251 results
8-K
EX-10
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
5 Mar 07
Entry into a Material Definitive Agreement
12:00am
December 31, 2003 and 2002, and as of and for the first
three quarters of 2004, and for the quarters of 2003; "SEC Investigation" means
the SEC's pending … investigation regarding certain matters in connection with the
Restatement; "Legacy Matters" means, collectively, any matters in connection
with the SEC
424B3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
5 Mar 07
Prospectus supplement
12:00am
indemnification obligations
to continuing and departing directors in connection with the ongoing SEC
investigation and related matters (the "Legacy … Liabilities, provided that the Company
shall approve any such disbursements for Legacy Liabilities other than the SEC
Investigation.
Interest
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
5 Mar 07
Entry into a Material Definitive Agreement
12:00am
in connection with the ongoing SEC
investigation and related matters (the "Legacy Liabilities"). The agreement
provides that the Fund may be disbursed … such disbursements for Legacy Liabilities other than the SEC
Investigation.
Interest accruing to the Fund will be returned to the Company quarterly.
Any
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
16 Apr 09
Other Events
12:00am
of Securities and Exchange Commission Investigation
Ligand Pharmaceuticals Incorporated (the “Company” or “Ligand”) has been advised by the U.S. Securities … and Exchange Commission (the “Commission”) that the investigation initiated by the Commission with regard to the circumstances surrounding the restatement
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
29 Jun 06
Ligand Announces Agreements to Settle Securities Class Action and Derivative Lawsuits
12:00am
made any admission of liability or wrongdoing. The related investigation by the Securities and Exchange Commission is ongoing and is not affected … of the settlements, payments, and the ongoing SEC investigation. Actual events or results may differ from Ligand’s expectations. There can be no assurance
424B3
fefe1msor 34r09t
29 Jun 06
Prospectus supplement
12:00am
424B3
yro90
10 May 07
Prospectus supplement
12:00am